Reverse Phase-High Performance Liquid Chromatography method development and validation for estimation of efavirenz by Quality by Design approach

  • Santosh A Waghmare JSPM’s Charak College of Pharmacy and Research(Affiliated to Savitribai Phule Pune University), Wagholi, Pune- 412207, India
  • Arun M Kashid Department of Pharmaceutical Chemistry, Sinhgad Institute of Pharmacy, Narhe, Pune 411041, Maharashtra, India
DOI https://doi.org/10.22270/jddt.v9i1-s.2357

Abstract

Quality by design (QbD) refers to the achievement of certain predictable quality with desired and predetermined specifications. A very useful component of the QbD is the understanding of factors and their interaction effects by a desired set of experiments by using software (design expert 8). The present study describes the development of a comprehensive science and risk based HPLC method which is given by design expert 8 and subsequent validation for the analysis of Efavirenz active pharmaceutical ingredient (API) using a quality by design approach. An efficient experimental design based on systematic scouting of all four key components of the RP‐HPLC method (column, pH, mobile phase and flow rate) is presented. The described method was linear. R2=0.9998. The precision, ruggedness and robustness values were also within the prescribed limits (<1% for system precision and <2% for other parameters). Chromatographic peak purity results indicated the absence of co‐eluting peaks with the main peak of Efavirenz. The proposed method can be used for routine analysis of Efavirenz in quality control laboratories.


Keywords: Quality by design, HPLC, Efavirenz, design expert 8.

Downloads

Download data is not yet available.

Author Biographies

Santosh A Waghmare, JSPM’s Charak College of Pharmacy and Research(Affiliated to Savitribai Phule Pune University), Wagholi, Pune- 412207, India

JSPM’s Charak College of Pharmacy and Research(Affiliated to Savitribai Phule Pune University), Wagholi, Pune- 412207, India

Arun M Kashid, Department of Pharmaceutical Chemistry, Sinhgad Institute of Pharmacy, Narhe, Pune 411041, Maharashtra, India

Department of Pharmaceutical Chemistry, Sinhgad Institute of Pharmacy, Narhe, Pune 411041, Maharashtra, India

References

1. Udaykumar RB, Stability- indicating HPLC method for the determination of efavirenz in bulk drug and in pharmaceutical dosage form, African Journal of Pharmacy and Pharmacology, 2009; 3(12):643-650.
2. Savie IM, Experimental design to quality by design in pharmaceutical legislation, Accreditation and Quality Assurance, 2012; 17:627-633.
3. Rajkotwala AS, Shaikh SS, QbD Approach to Analytical Method Development and Validation of Piracetam By HPLC, World Journal of Pharmacy and Pharmaceutical Sciences, 2016; 5(5):1771-1784
4. Venkata RY, Pal KA, Validated stability indicating analytical method and invitro dissolution studies of efavirenz formulation by RP-HPLC, International Journal of Pharmacy and Pharmaceutical Sciences, 2012; 4(l5):572-576.
5. Appala R, Simultaneous estimation of tenofovir disoproxil, emtricitabine and efavirenz in tablet dosage form by RP-HPLC, Oriental Journal of Chemistry, 2008; 24(2):645-650.
6. Brajendra SR, Method Development and Validation Of RP-HPLC Method In The Detection Of Efavirenz In Bulk Drug And Tablet Formulation, International Research Journal Of Pharmacy, 2012; 3(7):297-300.
7. Behnken DW, Some new three level designs for the study of quantitative variables, Technometrics, 1960; 2:455-475.
8. Bruns RE, Scarminio IS, Neto BB, Statistical design- Chemometrics, Amsterdam, 2006:338-350.
9. Bhavsar SA, RP-HPLC method for simultaneous estimation of tenofovir disoproxil fumarate, lamivudine, and efavirenz in combined tablet dosage form, Pharmaceutical Methods, 2012; 3(2):73–78.
10. Campana AM, Rodriguez, LC, Gonzalez, AL. Sequential response surface methodology for multioptimization in analytical with three-variable Doehlert designs, Analytical Chemica Acta, 1997; 348:237-246.
11. Doehlert, DH, Uniform shell designs, Journal of the Royal Statistical Society, 1970; 19:231-239.
12. Ermer J, Hans-JP, Validation in pharmaceutical analysis Part II: central importance of precision to establish acceptance criteria and for verifying and improving the quality of analytical data, Journal of Pharmaceutical and Biomedical Analysis, 2005; 37:859-870.
13. Fabre H, Robustness testing in liquid chromatography and capillary electrophoresis, Journal of Pharmaceutical and Biomedical Analysis, 1996; (14):1125-1132.
14. Gilmour SG, Response surface designs for experiments in bioprocessing’ Biometrics, 2006; (62):323-331.
Statistics
144 Views | 121 Downloads
How to Cite
Waghmare, S. A., & Kashid, A. M. (2019). Reverse Phase-High Performance Liquid Chromatography method development and validation for estimation of efavirenz by Quality by Design approach. Journal of Drug Delivery and Therapeutics, 9(1-s), 319-330. https://doi.org/10.22270/jddt.v9i1-s.2357
Issue
Vol 9 No 1-s (2019): Volume 9, Issue 1-s Jan-Feb 2019
Section
Research
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with this journal agree to the following terms:

 

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.

 

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.

 

  1. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

Â